Sandra Hadl
Overview
Explore the profile of Sandra Hadl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buerger V, Hadl S, Schneider M, Schaden M, Hochreiter R, Bitzer A, et al.
Lancet Infect Dis
. 2024 Sep;
25(1):114-125.
PMID: 39243794
Background: Chikungunya outbreaks have been reported in Brazil since 2014. Adolescents are a sensitive population who would benefit from a prophylactic vaccine. This study assessed the immunogenicity and safety of...
2.
McMahon R, Toepfer S, Sattler N, Schneider M, Narciso-Abraham M, Hadl S, et al.
Lancet Infect Dis
. 2024 Aug;
24(12):1383-1392.
PMID: 39146946
Background: Chikungunya virus infection can lead to long-term debilitating symptoms. A precursor phase 3 clinical study showed high seroprotection (defined as a 50% plaque reduction of chikungunya virus-specific neutralising antibodies...
3.
McMahon R, Fuchs U, Schneider M, Hadl S, Hochreiter R, Bitzer A, et al.
J Travel Med
. 2023 Dec;
31(2).
PMID: 38091981
Background: The global spread of the chikungunya virus (CHIKV) increases the exposure risk for individuals travelling to or living in endemic areas. This Phase 3 study was designed to demonstrate...
4.
Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, et al.
Lancet
. 2023 Jun;
401(10394):2138-2147.
PMID: 37321235
Background: VLA1553 is a live-attenuated vaccine candidate for active immunisation and prevention of disease caused by chikungunya virus. We report safety and immunogenicity data up to day 180 after vaccination...